Astrazeneca Pharma India informs about board meeting

Astrazeneca Pharma India Ltd. | Pharmaceuticals & Drugs | Healthcare | BSE: 506820 | NSE: ASTRAZEN

19 May 2021 Evaluate

Astrazeneca Pharma India has informed that a meeting of the Board of Directors of AstraZeneca Pharma India will be held on Tuesday, May 25, 2021, to consider and approve the Audited Financial Results of the Company for the quarter and year ended March 31, 2021. The Company further informed that the ‘Trading Window’ remains closed for all Designated Persons, from March 16, 2021 to May 27, 2021 in terms of AstraZeneca Pharma India - Code of Conduct for Prevention of Insider Trading framed under Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations 2015.

The above information is a part of company’s filings submitted to BSE.

Peers

Company Name	CMP
Sun Pharma. Inds.	1835.50
Dr. Reddys Labs.	1171.10
Cipla	1371.45
Lupin	2144.70
Zydus Lifesciences	1153.00
View more..

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045

Compliance Officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com	Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com	Telephone: +919860919463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com	Telephone: +919175899463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.